Yang Xiaoming, the prominent Chinese scientist who led the development of China’s first inactivated COVID-19 vaccine in 2020, has been expelled from his position in the National People’s Congress (NPC) due to alleged corruption. Yang, who served as chairman of China National Biotec Group (CNBG), a vaccine subsidiary of state-owned pharmaceutical giant Sinopharm, has been accused of serious disciplinary and legal violations, a term commonly associated with corruption in China.
State media reported on Monday that the 62-year-old scientist was dismissed from the NPC amid ongoing investigations. Yang’s removal marks a significant development in China’s ongoing crackdown on corruption, particularly within the healthcare sector, which has been the focus of a broader anti-corruption campaign initiated by President Xi Jinping in recent years.
A scientist at the forefront of the pandemic response
Yang Xiaoming is well-known for his critical role in China’s fight against the COVID-19 pandemic. He led a team of researchers that developed Sinopharm’s BBIBP-CorV vaccine, which was the first coronavirus shot approved for general use in China. The inactivated vaccine was approved for emergency use in December 2020, at a time when the global pandemic was at its height.
The virus was first detected in Wuhan, China, in late 2019, and by March 2020, it had spread worldwide, causing widespread illness and death. In the early stages of the pandemic, Sinopharm’s vaccine, along with Sinovac Biotech’s CoronaVac, became key tools in China’s domestic vaccination campaign and were also widely exported to other countries, helping to slow the spread of the virus.
Yang’s work during the pandemic earned him widespread recognition and honors. In September 2020, he was awarded a national accolade for his contributions to pandemic control and prevention. He was also recognized by the Chinese Society of Immunology as an outstanding scholar and received the prestigious Ho Leung Ho Lee Foundation award for his contributions to science and medicine.
Corruption allegations and investigations
Despite his accomplishments in vaccine development, Yang is now under investigation by China’s Central Commission for Discipline Inspection (CCDI), the country’s top anti-corruption body. The specific details of his alleged misconduct have not yet been disclosed, but the charge of “serious discipline and law violations” suggests the allegations are substantial.
Yang’s expulsion comes as part of a broader crackdown on corruption in China’s healthcare system, which has become a key focus of the government’s anti-graft campaign. The healthcare sector has long been plagued by corruption, particularly in the form of kickbacks and illegal payments involving hospitals, drug companies, and insurance funds. Since last year, dozens of hospital chiefs and medical professionals have been detained on similar charges.
The anti-corruption campaign, which has been one of President Xi Jinping’s hallmark initiatives, has expanded into various sectors, and the healthcare industry has become one of its major targets. This latest move against Yang underscores the government’s determination to root out corruption at all levels, even among those who were previously hailed as national heroes.
More Read
A widening crackdown in China’s healthcare sector
Yang’s case is not an isolated one. Earlier this year, Zhou Bin, a former senior executive at Sinopharm and the company’s deputy general manager, was also placed under investigation by the CCDI. This highlights a pattern of increasing scrutiny on major pharmaceutical companies and their executives, as the Chinese government seeks to clean up corruption in the industry.
The crackdown has reached various facets of China’s healthcare system, including hospitals, pharmaceutical firms, and medical insurance. The government’s efforts are part of a broader strategy to strengthen the integrity of public health services and ensure that corruption does not undermine the country’s healthcare infrastructure or its reputation globally.
Yang Xiaoming’s expulsion from China’s Parliament and the ongoing investigation mark a significant moment in the country’s efforts to address corruption within its healthcare system. Despite his pivotal role in developing China’s first COVID-19 vaccine and his earlier accolades, the allegations of corruption have now cast a shadow over his career. As China continues its anti-corruption drive, more high-profile figures in the healthcare sector may face similar scrutiny in the months to come.
